NFKB2 and colorectal carcinoma: Given that Rg5, which directly targets NFKB2, could can significantly suppressed PD‐L1 expression in CRC cells, we further evaluated the potential synergistic impacts of Rg5 treatment on the immunotherapy for PD1/PD‐L1 checkpoint were further evaluated.